Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62?? Annual ESPE Meeting 2024

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of OB, LUMO, PIK and PORT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. - LUMO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.